Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label, Single Ascending Dose and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered AIR-001 in Adults With AATD Due to PiZZ Genotype

NCT07431112 is registered in ClinicalTrials.gov with AIRNA Corporation as lead sponsor.

NCT NCT07431112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07431112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label, Single Ascending Dose and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered AIR-001 in Adults With AATD Due to PiZZ Genotype
Lead sponsor
AIRNA Corporation
Phase
Phase 1
Overall status
Recruiting
Start date
March 17, 2026
Completion date
January 31, 2029
Enrollment
54 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alpha 1 antitrypsin deficiency